Satellos Bioscience
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Satellos Bioscience is a Toronto clinical-stage biotechnology company established in 2018 to translate the muscle-stem-cell discoveries of scientific founder Dr. Michael Rudnicki, led by CEO and co-founder Frank Gleeson. It developed MyoReGenX, a proprietary discovery platform, and SAT-3247 — an oral small-molecule tablet (assigned the international name forazapadin) designed to restore muscle regeneration by correcting deficits in muscle stem cell polarity, initially targeting Duchenne muscular dystrophy.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Satellos is established in Canada to develop medicines that restore muscle regeneration, founded on Dr. Michael Rudnicki's discoveries.
- Public listing
Satellos completes a reverse takeover of iCo Therapeutics and begins trading on the TSX Venture Exchange (TSXV: MSCL), celebrating with a virtual market-open ceremony in September 2021.
- Nasdaq transition and Phase 2 trials
Satellos transitions to the Nasdaq Global Market (NASDAQ: MSLE) in February 2026, secures a $57.2 million equity financing, and initiates BASECAMP, a global placebo-controlled Phase 2 trial of SAT-3247 in children with Duchenne muscular dystrophy.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.